The news was a recapp on their meeting earlier this month at ASH and from all indications studies continue despite positive results as well as NO DILUTION for shareholders in order for additional financing. For those looking for FDA approval or a buy-out that was not on the table this morning. Stock traded down at .18 from .28 thus a loss for short term traders and an opportunity to buy the dip for those willing to buy and hold for 2017!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.